Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$41.99 - $62.38 $101 Million - $149 Million
-2,394,968 Reduced 98.44%
38,061 $2.24 Million
Q3 2023

Nov 14, 2023

BUY
$27.8 - $45.35 $18.2 Million - $29.7 Million
655,450 Added 36.87%
2,433,029 $106 Million
Q2 2023

Aug 14, 2023

BUY
$36.13 - $49.49 $239,830 - $328,514
6,638 Added 0.37%
1,777,579 $64.2 Million
Q1 2023

May 15, 2023

BUY
$36.54 - $54.26 $12.9 Million - $19.2 Million
354,213 Added 25.0%
1,770,941 $65.8 Million
Q4 2022

Feb 14, 2023

BUY
$41.27 - $98.62 $11.3 Million - $27 Million
273,973 Added 23.97%
1,416,728 $64.2 Million
Q3 2022

Nov 14, 2022

BUY
$59.5 - $86.7 $5.43 Million - $7.91 Million
91,225 Added 8.68%
1,142,755 $79.8 Million
Q2 2022

Aug 15, 2022

SELL
$39.16 - $88.71 $23.2 Million - $52.6 Million
-592,686 Reduced 36.05%
1,051,530 $70.6 Million
Q1 2022

May 16, 2022

SELL
$75.82 - $150.97 $40.2 Million - $80.1 Million
-530,583 Reduced 24.4%
1,644,216 $135 Million
Q4 2021

Feb 14, 2022

BUY
$132.01 - $190.29 $8 Million - $11.5 Million
60,589 Added 2.87%
2,174,799 $319 Million
Q3 2021

Nov 15, 2021

BUY
$132.13 - $177.45 $25.4 Million - $34.1 Million
192,431 Added 10.01%
2,114,210 $374 Million
Q2 2021

Aug 16, 2021

BUY
$144.0 - $179.73 $56.1 Million - $70 Million
389,279 Added 25.4%
1,921,779 $310 Million
Q1 2021

May 17, 2021

SELL
$158.92 - $221.61 $4.28 Million - $5.96 Million
-26,916 Reduced 1.73%
1,532,500 $263 Million
Q4 2020

Feb 16, 2021

BUY
$162.05 - $240.27 $253 Million - $375 Million
1,559,416 New
1,559,416 $343 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.